Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections.

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or symptoms in adult ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous ...

There is a simple discount patient access scheme for fedratinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

In more than 7% of athletes, baseline spleen size met current criteria for splenomegaly. Conclusions: There is a wide range of normal spleen size among collegiate athletes. Average spleen size was ...

These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources ...

The appraisal committee has prepared final draft guidance (FDG) on fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) and submitted it to NICE. The FDG ...

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based ...